Antipsychotics

Prochlorperazine is a piperazine phenothiazine dopamine D2 antagonist with powerful antiemetic and vestibular-suppressant properties on the WHO Model List of Essential Medicines. It blocks D2 receptors in the chemoreceptor trigger zone (CTZ) of the medulla oblongata and vestibular nuclei, relieving vertigo and suppressing vomiting. Indicated for severe nausea and vomiting, vertigo associated with Meniere's disease or labyrinthitis, and acute migraine attacks.

Flupentixol is a thioxanthene typical antipsychotic. At low doses (1-3 mg/day), it blocks presynaptic dopamine autoreceptors, stimulating dopamine turnover and exerting disinhibiting, mood-elevating, and anxiolytic effects; at higher doses, it blocks postsynaptic D2 receptors to control hallucinations and delusions. Indicated for maintenance treatment of schizophrenia, paranoid psychoses, and low-dose management of chronic depression with apathy.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Chlordiazepoxide and Trifluoperazine combines an anxiolytic benzodiazepine with a high-potency phenothiazine antipsychotic. Trifluoperazine blocks postsynaptic dopamine D2 receptors in the mesolimbic pathway, subduing agitation and delusional thinking, while chlordiazepoxide modulates GABAA receptors to control anxiety and somatic tension. Indicated for anxiety states complicated by somatic obsessions, severe agitation, or mild psychotic symptoms.

Olanzapine is a second-generation atypical thienobenzodiazepine antipsychotic and mood stabilizer on the WHO Model List of Essential Medicines. It acts by antagonizing serotonin 5-HT2A and dopamine D2 receptors, with high affinity for 5-HT2C, H1, and alpha-1 receptors, delivering potent antipsychotic efficacy with low extrapyramidal liability. Indicated for schizophrenia, acute manic or mixed episodes in bipolar I disorder, maintenance in bipolar disorder, and treatment-resistant depression (in combination with fluoxetine).

Olanzapine is a second-generation atypical thienobenzodiazepine antipsychotic and mood stabilizer on the WHO Model List of Essential Medicines. It acts by antagonizing serotonin 5-HT2A and dopamine D2 receptors, with high affinity for 5-HT2C, H1, and alpha-1 receptors, delivering potent antipsychotic efficacy with low extrapyramidal liability. Indicated for schizophrenia, acute manic or mixed episodes in bipolar I disorder, maintenance in bipolar disorder, and treatment-resistant depression (in combination with fluoxetine).

Quetiapine Fumarate is a dibenzothiazepine atypical antipsychotic. It exhibits antagonist activity at serotonin 5-HT2A and dopamine D2 receptors, with rapid dissociation from D2 receptors ("hit-and-run" kinetics) which minimizes extrapyramidal symptoms and hyperprolactinemia. Its active metabolite, norquetiapine, potently inhibits norepinephrine reuptake (NET) and acts as a 5-HT1A partial agonist, conferring distinctive antidepressant efficacy. Indicated for schizophrenia, acute manic episodes in bipolar I disorder, bipolar depression, and adjunctive therapy in major depressive disorder.

Quetiapine Fumarate is a dibenzothiazepine atypical antipsychotic. It exhibits antagonist activity at serotonin 5-HT2A and dopamine D2 receptors, with rapid dissociation from D2 receptors ("hit-and-run" kinetics) which minimizes extrapyramidal symptoms and hyperprolactinemia. Its active metabolite, norquetiapine, potently inhibits norepinephrine reuptake (NET) and acts as a 5-HT1A partial agonist, conferring distinctive antidepressant efficacy. Indicated for schizophrenia, acute manic episodes in bipolar I disorder, bipolar depression, and adjunctive therapy in major depressive disorder.

Risperidone and Trihexyphenidyl (Benzhexol) is a therapeutic combination designed to provide antipsychotic efficacy while preventing drug-induced movement disorders. Risperidone, a benzisoxazole atypical antipsychotic, blocks dopamine D2 and serotonin 5-HT2A receptors to control psychosis, while trihexyphenidyl, a centrally acting anticholinergic agent, blocks muscarinic M1 receptors to restore the dopamine-acetylcholine balance in the basal ganglia, preventing extrapyramidal symptoms (acute dystonia, parkinsonian rigidity, tremors, akathisia). Indicated for schizophrenia, schizoaffective disorder, and severe psychotic agitation complicated by high extrapyramidal risk.

Risperidone is a benzisoxazole second-generation atypical antipsychotic on the WHO Model List of Essential Medicines. It possesses high-affinity antagonism at serotonin 5-HT2A and dopamine D2 receptors, as well as alpha-1 and alpha-2 adrenergic and H1 receptors. Indicated for schizophrenia in adults and adolescents, acute mania in bipolar I disorder, and irritability/severe aggression associated with autistic disorder in children.

Aripiprazole is a third-generation quinolinone atypical antipsychotic functioning as a dopamine-serotonin system stabilizer. It acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. By acting as a partial agonist, it buffers hyperactive dopamine in mesolimbic circuits (alleviating positive symptoms) while supporting dopamine activity in mesocortical circuits (improving negative symptoms and avoiding parkinsonism and hyperprolactinemia). Indicated for schizophrenia, acute manic/mixed bipolar episodes, adjunctive treatment in major depression, and Tourette's disorder.

Quetiapine Fumarate is a dibenzothiazepine atypical antipsychotic. It exhibits antagonist activity at serotonin 5-HT2A and dopamine D2 receptors, with rapid dissociation from D2 receptors ("hit-and-run" kinetics) which minimizes extrapyramidal symptoms and hyperprolactinemia. Its active metabolite, norquetiapine, potently inhibits norepinephrine reuptake (NET) and acts as a 5-HT1A partial agonist, conferring distinctive antidepressant efficacy. Indicated for schizophrenia, acute manic episodes in bipolar I disorder, bipolar depression, and adjunctive therapy in major depressive disorder.

Flupentixol and Melitracen is a classic psychoanaleptic fixed-dose combination. Flupentixol, a thioxanthene derivative, acts at low doses (0.5 mg) preferentially on presynaptic dopamine autoreceptors to increase dopaminergic tone and relieve apathy and anxiety, while melitracen, a bipolar tricyclic antidepressant, inhibits norepinephrine and serotonin reuptake. Together, they provide activating, anxiolytic, and mood-lifting action without causing marked sedation. Indicated for psychogenic depression, depressive neuroses, masked depression, and psychosomatic disorders accompanied by anxiety and apathy.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Aripiprazole is a third-generation quinolinone atypical antipsychotic functioning as a dopamine-serotonin system stabilizer. It acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. By acting as a partial agonist, it buffers hyperactive dopamine in mesolimbic circuits (alleviating positive symptoms) while supporting dopamine activity in mesocortical circuits (improving negative symptoms and avoiding parkinsonism and hyperprolactinemia). Indicated for schizophrenia, acute manic/mixed bipolar episodes, adjunctive treatment in major depression, and Tourette's disorder.

Aripiprazole is a third-generation quinolinone atypical antipsychotic functioning as a dopamine-serotonin system stabilizer. It acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. By acting as a partial agonist, it buffers hyperactive dopamine in mesolimbic circuits (alleviating positive symptoms) while supporting dopamine activity in mesocortical circuits (improving negative symptoms and avoiding parkinsonism and hyperprolactinemia). Indicated for schizophrenia, acute manic/mixed bipolar episodes, adjunctive treatment in major depression, and Tourette's disorder.

Aripiprazole is a third-generation quinolinone atypical antipsychotic functioning as a dopamine-serotonin system stabilizer. It acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. By acting as a partial agonist, it buffers hyperactive dopamine in mesolimbic circuits (alleviating positive symptoms) while supporting dopamine activity in mesocortical circuits (improving negative symptoms and avoiding parkinsonism and hyperprolactinemia). Indicated for schizophrenia, acute manic/mixed bipolar episodes, adjunctive treatment in major depression, and Tourette's disorder.

Aripiprazole is a third-generation quinolinone atypical antipsychotic functioning as a dopamine-serotonin system stabilizer. It acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. By acting as a partial agonist, it buffers hyperactive dopamine in mesolimbic circuits (alleviating positive symptoms) while supporting dopamine activity in mesocortical circuits (improving negative symptoms and avoiding parkinsonism and hyperprolactinemia). Indicated for schizophrenia, acute manic/mixed bipolar episodes, adjunctive treatment in major depression, and Tourette's disorder.

Aripiprazole is a third-generation quinolinone atypical antipsychotic functioning as a dopamine-serotonin system stabilizer. It acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. By acting as a partial agonist, it buffers hyperactive dopamine in mesolimbic circuits (alleviating positive symptoms) while supporting dopamine activity in mesocortical circuits (improving negative symptoms and avoiding parkinsonism and hyperprolactinemia). Indicated for schizophrenia, acute manic/mixed bipolar episodes, adjunctive treatment in major depression, and Tourette's disorder.

Aripiprazole is a third-generation quinolinone atypical antipsychotic functioning as a dopamine-serotonin system stabilizer. It acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. By acting as a partial agonist, it buffers hyperactive dopamine in mesolimbic circuits (alleviating positive symptoms) while supporting dopamine activity in mesocortical circuits (improving negative symptoms and avoiding parkinsonism and hyperprolactinemia). Indicated for schizophrenia, acute manic/mixed bipolar episodes, adjunctive treatment in major depression, and Tourette's disorder.

Chlorpromazine is the historic prototype aliphatic phenothiazine first-generation typical antipsychotic on the WHO Model List of Essential Medicines. It blocks postsynaptic dopamine D2 receptors in the mesolimbic pathway, while also producing strong blockade of alpha-1 adrenergic, histaminergic H1, and muscarinic receptors, causing marked sedation and autonomic stabilization. Indicated for schizophrenia, acute manic excitement, severe behavioral problems, intractable hiccups, and acute porphyria.

Chlorpromazine is the historic prototype aliphatic phenothiazine first-generation typical antipsychotic on the WHO Model List of Essential Medicines. It blocks postsynaptic dopamine D2 receptors in the mesolimbic pathway, while also producing strong blockade of alpha-1 adrenergic, histaminergic H1, and muscarinic receptors, causing marked sedation and autonomic stabilization. Indicated for schizophrenia, acute manic excitement, severe behavioral problems, intractable hiccups, and acute porphyria.

Chlorpromazine is the historic prototype aliphatic phenothiazine first-generation typical antipsychotic on the WHO Model List of Essential Medicines. It blocks postsynaptic dopamine D2 receptors in the mesolimbic pathway, while also producing strong blockade of alpha-1 adrenergic, histaminergic H1, and muscarinic receptors, causing marked sedation and autonomic stabilization. Indicated for schizophrenia, acute manic excitement, severe behavioral problems, intractable hiccups, and acute porphyria.

Clozapine is a dibenzodiazepine prototype atypical antipsychotic on the WHO Model List of Essential Medicines. It possesses weak affinity for dopamine D2 receptors and potent blockade of D4, 5-HT2A, alpha-1, and muscarinic receptors. Demonstrates unique superiority in reducing suicidal behavior and treating refractory psychosis without producing extrapyramidal symptoms or tardive dyskinesia. Strictly reserved for treatment-resistant schizophrenia and reducing suicidal behavior in schizophrenia or schizoaffective disorder.

Clozapine is a dibenzodiazepine prototype atypical antipsychotic on the WHO Model List of Essential Medicines. It possesses weak affinity for dopamine D2 receptors and potent blockade of D4, 5-HT2A, alpha-1, and muscarinic receptors. Demonstrates unique superiority in reducing suicidal behavior and treating refractory psychosis without producing extrapyramidal symptoms or tardive dyskinesia. Strictly reserved for treatment-resistant schizophrenia and reducing suicidal behavior in schizophrenia or schizoaffective disorder.

Clozapine is a dibenzodiazepine prototype atypical antipsychotic on the WHO Model List of Essential Medicines. It possesses weak affinity for dopamine D2 receptors and potent blockade of D4, 5-HT2A, alpha-1, and muscarinic receptors. Demonstrates unique superiority in reducing suicidal behavior and treating refractory psychosis without producing extrapyramidal symptoms or tardive dyskinesia. Strictly reserved for treatment-resistant schizophrenia and reducing suicidal behavior in schizophrenia or schizoaffective disorder.

Fluoxetine Hydrochloride is a prototype selective serotonin reuptake inhibitor (SSRI) on the WHO Model List of Essential Medicines. It blocks the presynaptic serotonin transporter (SERT) and possesses a long elimination half-life (1-3 days for parent drug, 7-15 days for active norfluoxetine), providing a built-in buffer against abrupt discontinuation syndrome. Also displays mild 5-HT2C antagonism, contributing to energizing/activating effects. Indicated for major depressive disorder, obsessive-compulsive disorder (OCD), bulimia nervosa, and panic disorder.

Risperidone is a benzisoxazole second-generation atypical antipsychotic on the WHO Model List of Essential Medicines. It possesses high-affinity antagonism at serotonin 5-HT2A and dopamine D2 receptors, as well as alpha-1 and alpha-2 adrenergic and H1 receptors. Indicated for schizophrenia in adults and adolescents, acute mania in bipolar I disorder, and irritability/severe aggression associated with autistic disorder in children.

Risperidone is a benzisoxazole second-generation atypical antipsychotic on the WHO Model List of Essential Medicines. It possesses high-affinity antagonism at serotonin 5-HT2A and dopamine D2 receptors, as well as alpha-1 and alpha-2 adrenergic and H1 receptors. Indicated for schizophrenia in adults and adolescents, acute mania in bipolar I disorder, and irritability/severe aggression associated with autistic disorder in children.

Risperidone is a benzisoxazole second-generation atypical antipsychotic on the WHO Model List of Essential Medicines. It possesses high-affinity antagonism at serotonin 5-HT2A and dopamine D2 receptors, as well as alpha-1 and alpha-2 adrenergic and H1 receptors. Indicated for schizophrenia in adults and adolescents, acute mania in bipolar I disorder, and irritability/severe aggression associated with autistic disorder in children.

Ziprasidone is an atypical antipsychotic featuring a high 5-HT2A/D2 receptor binding ratio, potent 5-HT1A agonism, 5-HT1D and 5-HT2C antagonism, and moderate inhibition of synaptic serotonin and norepinephrine reuptake. Demonstrates very low propensity for weight gain, diabetes, and hyperlipidemia. Indicated for schizophrenia and acute manic or mixed episodes in bipolar I disorder.

Ziprasidone is an atypical antipsychotic featuring a high 5-HT2A/D2 receptor binding ratio, potent 5-HT1A agonism, 5-HT1D and 5-HT2C antagonism, and moderate inhibition of synaptic serotonin and norepinephrine reuptake. Demonstrates very low propensity for weight gain, diabetes, and hyperlipidemia. Indicated for schizophrenia and acute manic or mixed episodes in bipolar I disorder.

Nortriptyline Hydrochloride is a secondary amine tricyclic antidepressant and the active demethylated metabolite of amitriptyline. It selectively inhibits the reuptake of norepinephrine over serotonin, offering effective antidepressant and neuropathic analgesia with significantly less sedation, anticholinergic burden, and orthostatic hypotension than amitriptyline. Indicated for major depressive disorder and chronic neuropathic pain syndromes.

Quetiapine Fumarate is a dibenzothiazepine atypical antipsychotic. It exhibits antagonist activity at serotonin 5-HT2A and dopamine D2 receptors, with rapid dissociation from D2 receptors ("hit-and-run" kinetics) which minimizes extrapyramidal symptoms and hyperprolactinemia. Its active metabolite, norquetiapine, potently inhibits norepinephrine reuptake (NET) and acts as a 5-HT1A partial agonist, conferring distinctive antidepressant efficacy. Indicated for schizophrenia, acute manic episodes in bipolar I disorder, bipolar depression, and adjunctive therapy in major depressive disorder.

Clozapine is a dibenzodiazepine prototype atypical antipsychotic on the WHO Model List of Essential Medicines. It possesses weak affinity for dopamine D2 receptors and potent blockade of D4, 5-HT2A, alpha-1, and muscarinic receptors. Demonstrates unique superiority in reducing suicidal behavior and treating refractory psychosis without producing extrapyramidal symptoms or tardive dyskinesia. Strictly reserved for treatment-resistant schizophrenia and reducing suicidal behavior in schizophrenia or schizoaffective disorder.

Quetiapine Fumarate is a dibenzothiazepine atypical antipsychotic. It exhibits antagonist activity at serotonin 5-HT2A and dopamine D2 receptors, with rapid dissociation from D2 receptors ("hit-and-run" kinetics) which minimizes extrapyramidal symptoms and hyperprolactinemia. Its active metabolite, norquetiapine, potently inhibits norepinephrine reuptake (NET) and acts as a 5-HT1A partial agonist, conferring distinctive antidepressant efficacy. Indicated for schizophrenia, acute manic episodes in bipolar I disorder, bipolar depression, and adjunctive therapy in major depressive disorder.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Cariprazine is an advanced third-generation atypical antipsychotic that acts as a potent dopamine D3-preferring D2 partial agonist and 5-HT1A partial agonist. Its 10-fold higher affinity for D3 receptors over D2 provides notable improvements in negative symptoms, cognitive deficits, and mood stability in psychotic illnesses. It features an ultra-long-acting active metabolite (didesmethylcariprazine, DDCAR) with an elimination half-life of 1 to 3 weeks. Indicated for schizophrenia in adults, acute manic/mixed episodes in bipolar I disorder, and bipolar depression.

Cariprazine is an advanced third-generation atypical antipsychotic that acts as a potent dopamine D3-preferring D2 partial agonist and 5-HT1A partial agonist. Its 10-fold higher affinity for D3 receptors over D2 provides notable improvements in negative symptoms, cognitive deficits, and mood stability in psychotic illnesses. It features an ultra-long-acting active metabolite (didesmethylcariprazine, DDCAR) with an elimination half-life of 1 to 3 weeks. Indicated for schizophrenia in adults, acute manic/mixed episodes in bipolar I disorder, and bipolar depression.

Cariprazine is an advanced third-generation atypical antipsychotic that acts as a potent dopamine D3-preferring D2 partial agonist and 5-HT1A partial agonist. Its 10-fold higher affinity for D3 receptors over D2 provides notable improvements in negative symptoms, cognitive deficits, and mood stability in psychotic illnesses. It features an ultra-long-acting active metabolite (didesmethylcariprazine, DDCAR) with an elimination half-life of 1 to 3 weeks. Indicated for schizophrenia in adults, acute manic/mixed episodes in bipolar I disorder, and bipolar depression.

Cariprazine is an advanced third-generation atypical antipsychotic that acts as a potent dopamine D3-preferring D2 partial agonist and 5-HT1A partial agonist. Its 10-fold higher affinity for D3 receptors over D2 provides notable improvements in negative symptoms, cognitive deficits, and mood stability in psychotic illnesses. It features an ultra-long-acting active metabolite (didesmethylcariprazine, DDCAR) with an elimination half-life of 1 to 3 weeks. Indicated for schizophrenia in adults, acute manic/mixed episodes in bipolar I disorder, and bipolar depression.

Lurasidone Hydrochloride is a benzoisothiazole second-generation atypical antipsychotic. It acts as an antagonist at dopamine D2 and 5-HT2A receptors, with potent partial agonism at 5-HT1A and high antagonism at 5-HT7 receptors, while lacking anticholinergic and H1 antihistaminic properties, offering an exceptionally clean metabolic profile with minimal weight gain or sedation. Indicated for schizophrenia and depressive episodes associated with bipolar I disorder (bipolar depression).

Lurasidone Hydrochloride is a benzoisothiazole second-generation atypical antipsychotic. It acts as an antagonist at dopamine D2 and 5-HT2A receptors, with potent partial agonism at 5-HT1A and high antagonism at 5-HT7 receptors, while lacking anticholinergic and H1 antihistaminic properties, offering an exceptionally clean metabolic profile with minimal weight gain or sedation. Indicated for schizophrenia and depressive episodes associated with bipolar I disorder (bipolar depression).

Lurasidone Hydrochloride is a benzoisothiazole second-generation atypical antipsychotic. It acts as an antagonist at dopamine D2 and 5-HT2A receptors, with potent partial agonism at 5-HT1A and high antagonism at 5-HT7 receptors, while lacking anticholinergic and H1 antihistaminic properties, offering an exceptionally clean metabolic profile with minimal weight gain or sedation. Indicated for schizophrenia and depressive episodes associated with bipolar I disorder (bipolar depression).

Risperidone and Trihexyphenidyl (Benzhexol) is a therapeutic combination designed to provide antipsychotic efficacy while preventing drug-induced movement disorders. Risperidone, a benzisoxazole atypical antipsychotic, blocks dopamine D2 and serotonin 5-HT2A receptors to control psychosis, while trihexyphenidyl, a centrally acting anticholinergic agent, blocks muscarinic M1 receptors to restore the dopamine-acetylcholine balance in the basal ganglia, preventing extrapyramidal symptoms (acute dystonia, parkinsonian rigidity, tremors, akathisia). Indicated for schizophrenia, schizoaffective disorder, and severe psychotic agitation complicated by high extrapyramidal risk.

Risperidone and Trihexyphenidyl (Benzhexol) is a therapeutic combination designed to provide antipsychotic efficacy while preventing drug-induced movement disorders. Risperidone, a benzisoxazole atypical antipsychotic, blocks dopamine D2 and serotonin 5-HT2A receptors to control psychosis, while trihexyphenidyl, a centrally acting anticholinergic agent, blocks muscarinic M1 receptors to restore the dopamine-acetylcholine balance in the basal ganglia, preventing extrapyramidal symptoms (acute dystonia, parkinsonian rigidity, tremors, akathisia). Indicated for schizophrenia, schizoaffective disorder, and severe psychotic agitation complicated by high extrapyramidal risk.

Trifluoperazine is a high-potency piperazine phenothiazine typical antipsychotic. It potently blocks postsynaptic dopamine D2 receptors in the mesolimbic and nigrostriatal systems, producing robust anti-hallucinatory and anti-delusional effects with low sedation and low autonomic burden, but high propensity for extrapyramidal movement disorders. Indicated for schizophrenia, other psychotic disorders, and short-term non-psychotic anxiety.

Trifluoperazine is a high-potency piperazine phenothiazine typical antipsychotic. It potently blocks postsynaptic dopamine D2 receptors in the mesolimbic and nigrostriatal systems, producing robust anti-hallucinatory and anti-delusional effects with low sedation and low autonomic burden, but high propensity for extrapyramidal movement disorders. Indicated for schizophrenia, other psychotic disorders, and short-term non-psychotic anxiety.